Vimarsana
Biggest News Aggregation in the World

Page 4 - Observational Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Observational Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Observational Study Today - Breaking & Trending Today

Without RCT FDA May Consider Estrogen Approval For Gender Incongruence - Vimarsana News

Without RCT FDA May Consider Estrogen Approval For Gender Incongruence

The FDA may consider approval of the cross-sex hormone estradiol for gender incongruence in adults and minors based on an observational study and not an RCT with placebo.

Source: forbes.com
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting - Vimarsana News

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support...

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndr - Vimarsana News

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndr

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification –– Analysis of 72 patients treated in STK-001 clinical trials suggests that higher...

Upadacitinib Demonstrates Efficacy in RA Treatment Regardless of Patient's Baseline CRP Levels - Vimarsana News

Upadacitinib Demonstrates Efficacy in RA Treatment Regardless of Patient's Baseline CRP Levels

In a real-world, prospective study, upadacitinib demonstrated great potential for the treatment of rheumatoid arthritis (RA) regardless of a patient’s baseline C-reactive protein (CRP) levels.

Source: ajmc.com
Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting -November 21, 2023 at 08:05 am EST - Vimarsana News

Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting -November 21, 2023 at 08:05 am EST

– New data include 24-month results from the largest and longest prospective natural history study of children and adolescents with Dravet syndrome, which showed a lack of improvement despite...